Endpoint
Triglycerides
CAT:outcome/serum-triglyceridesreported in mg/dL
Method
Serum or plasma triglyceride concentration by clinical enzymatic (glycerol-phosphate-oxidase) assay in a sample drawn after a stated fast. Fast duration is recorded on the edge, because postprandial triglycerides are several-fold higher than fasting values.
The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.
Notes
Three distinct confusions. (1) The analyte and the intervention share a name: medium-chain triglycerides administered as the treatment (PMIDs 38936302, 25636220 and the MCT block) are an exposure, not this endpoint, and an extractor keying on the word alone will invert the edge's direction of causation. (2) LDL cholesterol derived by the Friedewald equation SUBTRACTS triglycerides/5, so where LDL-C was calculated rather than directly assayed the two are algebraically linked and a triglyceride change mechanically produces an apparent LDL-C change; the LDL-C method must be on the edge before both are carried. (3) Total cholesterol shares the unit but not the conversion constant — triglycerides convert mg/dL to mmol/L by 88.57, cholesterols by 38.67, so any single 'lipid' node with one constant corrupts one of them.
Findings
1 finding from 1 compound, strongest first.
curcumin — no detected effect on
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 373
- Population
- adults with type 2 diabetes mellitus (T2DM)